SYBX vs. TCRT, LUMO, BIVI, ORGS, NRBO, KALA, MEIP, COCP, BNTC, and INDP
Should you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Alaunos Therapeutics (TCRT), Lumos Pharma (LUMO), BioVie (BIVI), Orgenesis (ORGS), NeuroBo Pharmaceuticals (NRBO), KALA BIO (KALA), MEI Pharma (MEIP), Cocrystal Pharma (COCP), Benitec Biopharma (BNTC), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical preparations" industry.
Alaunos Therapeutics (NASDAQ:TCRT) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation.
Synlogic received 324 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. Likewise, 69.54% of users gave Synlogic an outperform vote while only 58.33% of users gave Alaunos Therapeutics an outperform vote.
27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 5.1% of Alaunos Therapeutics shares are owned by insiders. Comparatively, 8.0% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Alaunos Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500. Comparatively, Synlogic has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.
Alaunos Therapeutics has a net margin of 0.00% compared to Alaunos Therapeutics' net margin of -2,284.65%. Alaunos Therapeutics' return on equity of -189.99% beat Synlogic's return on equity.
Alaunos Therapeutics has higher earnings, but lower revenue than Synlogic.
In the previous week, Synlogic had 8 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 10 mentions for Synlogic and 2 mentions for Alaunos Therapeutics. Synlogic's average media sentiment score of 0.69 beat Alaunos Therapeutics' score of -0.16 indicating that Alaunos Therapeutics is being referred to more favorably in the media.
Synlogic has a consensus price target of $65.00, suggesting a potential upside of 3,839.39%. Given Alaunos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Synlogic is more favorable than Alaunos Therapeutics.
Summary
Synlogic beats Alaunos Therapeutics on 12 of the 15 factors compared between the two stocks.
Get Synlogic News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Synlogic Competitors List
Related Companies and Tools
